Trial · NCT00699192
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 27
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Angina pectoris | Cardiac disorders | Amlodipine/Valsartan 5/80 mg | 1 | 274 | |
| serious | Angina pectoris | Cardiac disorders | Amlodipine/Valsartan 5/40 mg | 0 | 272 | |
| serious | Angina pectoris | Cardiac disorders | Amlodipine 5 mg | 0 | 272 | |
| serious | Atrial fibrillation | Cardiac disorders | Amlodipine/Valsartan 5/80 mg | 1 | 274 | |
| serious | Atrial fibrillation | Cardiac disorders | Amlodipine/Valsartan 5/40 mg | 0 | 272 | |
| serious | Atrial fibrillation | Cardiac disorders | Amlodipine 5 mg | 0 | 272 | |
| serious | Tachyarrhythmia | Cardiac disorders | Amlodipine/Valsartan 5/80 mg | 0 | 274 | |
| serious | Tachyarrhythmia | Cardiac disorders | Amlodipine/Valsartan 5/40 mg | 0 | 272 | |
| serious | Tachyarrhythmia | Cardiac disorders | Amlodipine 5 mg | 1 | 272 | |
| serious | Ophthalmoplegia | Eye disorders | Amlodipine/Valsartan 5/80 mg | 0 | 274 | |
| serious | Ophthalmoplegia | Eye disorders | Amlodipine/Valsartan 5/40 mg | 1 | 272 | |
| serious | Ophthalmoplegia | Eye disorders | Amlodipine 5 mg | 0 | 272 | |
| serious | Back pain | Musculoskeletal and connective tissue disorders | Amlodipine/Valsartan 5/80 mg | 1 | 274 | |
| serious | Back pain | Musculoskeletal and connective tissue disorders | Amlodipine/Valsartan 5/40 mg | 0 | 272 | |
| serious | Back pain | Musculoskeletal and connective tissue disorders | Amlodipine 5 mg | 0 | 272 | |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Amlodipine/Valsartan 5/80 mg | 0 | 274 | |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Amlodipine/Valsartan 5/40 mg | 1 | 272 | |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Amlodipine 5 mg | 0 | 272 | |
| serious | Lentigo maligna stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Amlodipine/Valsartan 5/80 mg | 1 | 274 | |
| serious | Lentigo maligna stage unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Amlodipine/Valsartan 5/40 mg | 0 | 272 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00699192/events